카보프로스트 트로메타민 시장 점유율, 규모, 동향, 산업 분석 보고서 : 용도별, 유통 채널별, 지역별, 부문별 예측(2024-2032년)

The global carboprost tromethamine market size is expected to reach USD 2,100.63 million by 2032, according to a new study by Polaris Market Research. The report "Carboprost Tromethamine Market Share, Size, Trends, Industry Analysis Report, By Application (Pregnancy Abortion, Postpartum Hemorrhage Treatment); By Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Carboprost tromethamine, commonly known as Hemabate, is a prostaglandin employed in the management of postpartum hemorrhage and severe bleeding following childbirth in women. It also serves as a contraceptive pill, inducing abortion by facilitating the gradual expulsion of the placenta and initiating uterine contractions. This drug is administered between the third and fifth month of pregnancy. Its mechanism involves heightened contractions by acting on the F receptor or the E2 receptor sites within the uterine muscles.

The evolving landscape of the market is shaped by a growing emphasis on maternal healthcare and the introduction of initiatives targeted at diminishing maternal mortality rates. Globally, governments and healthcare organizations are taking proactive measures to improve access to high-quality maternal healthcare services, which includes ensuring the accessibility of vital medications like carboprost tromethamine. Furthermore, the constant progress in medical research and technology has resulted in the creation of inventive formulations and delivery approaches for carboprost tromethamine, thereby broadening its market prospects.

Nonetheless, obstacles like the elevated cost of treatment and potential side effects linked to carboprost tromethamine could impede its broad adoption. Like any medication, patient safety considerations come into play, prompting healthcare professionals to balance the benefits and risks when recommending carboprost tromethamine carefully. Industry participants are proactively involved in research and development endeavors to tackle these challenges, aiming to improve the drug's safety profile and alleviate its economic impact on patients.

Further, geographically, the global reach of the carboprost tromethamine market is evident, with substantial dominance in developed regions like North America and Europe. These areas feature established healthcare infrastructures, strong regulatory frameworks, and heightened awareness regarding maternal health concerns. Nevertheless, initiatives are underway to broaden the market influence in emerging economies, reflecting an increasing focus on enhancing maternal healthcare outcomes in these regions.

Carboprost Tromethamine Market Report Highlights

In 2023, the pregnancy abortion segment is expected to witness highest growth during forecast period owing to regulatory changes and policies surrounding abortion practices

Hospital pharmacies segment is expected to dominate the carboprost tromethamine market during forecast period. This is attributed to the integration of advanced therapeutic options

In 2023, North America accounted for the largest revenue share due to presence of major players, technological advancements, and robust healthcare infrastructure.

The market is highly competitive owing to the existence of market players with a global presence, including Hikma Pharmaceuticals PLC, JHP Pharmaceuticals, LLC, LGM Pharma, Pfizer Inc., Pharmacia and Upjohn Company LLC (a division of Pfizer Inc.), Sandoz Inc. (a Novartis Division), Sun Pharmaceutical Industries Ltd, among others.

Polaris Market Research has segmented the carboprost tromethamine market report based on application, distribution channel, and region:

Carboprost Tromethamine, Application Outlook (Revenue - USD Million, 2019 - 2032)

• Pregnancy Abortion
• Postpartum Hemorrhage Treatment

Carboprost Tromethamine, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

• Hospital Pharmacies
• Drug Stores
• Others

Carboprost Tromethamine, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• France
• Germany
• UK
• Italy
• Netherlands
• Spain
• Russia
• Asia Pacific
• Japan
• China
• India
• Malaysia
• Indonesia
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• Saudi Arabia
• UAE
• Israel
• South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Carboprost Tromethamine Market Insights

• 4.1. Carboprost Tromethamine Market - Industry Snapshot
• 4.2. Carboprost Tromethamine Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Rising pregnancy is projected to spur the product demand
    • 4.2.1.2. Increased number of FDA approval is expected to drive market growth
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Lack of skilled healthcare professional is likely to impede the market carboprost tromethamine growth opportunities
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Carboprost Tromethamine Industry trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Carboprost Tromethamine Market, by Application

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Carboprost Tromethamine, by Application, 2019-2032 (USD Million)
• 5.3. Pregnancy Abortion
  • 5.3.1. Global Carboprost Tromethamine Market, by Pregnancy Abortion, by Region, 2019-2032 (USD Million)
• 5.4. Postpartum Hemorrhage Treatment
  • 5.4.1. Global Carboprost Tromethamine Market, by Postpartum Hemorrhage Treatment, by Region, 2019-2032 (USD Million)

6. Global Carboprost Tromethamine Market, by Distribution Channel

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
• 6.3. Hospital Pharmacies
  • 6.3.1. Global Carboprost Tromethamine Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Million)
• 6.4. Drug Stores
  • 6.4.1. Global Carboprost Tromethamine Market, by Drug Stores, by Region, 2019-2032 (USD Million)
• 6.5. Others
  • 6.5.1. Global Carboprost Tromethamine Market, by Others, by Region, 2019-2032 (USD Million)

7. Global Carboprost Tromethamine Market, by Geography

• 7.1. Key findings
• 7.2. Introduction
  • 7.2.1. Carboprost Tromethamine Market Assessment, By Geography, 2019-2032 (USD Million)
• 7.3. Carboprost Tromethamine Market - North America
  • 7.3.1. North America: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.3.2. North America: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.3.3. Carboprost Tromethamine Market - U.S.
    • 7.3.3.1. U.S.: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.3.3.2. U.S.: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.3.4. Carboprost Tromethamine Market - Canada
    • 7.3.4.1. Canada: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.3.4.2. Canada: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
• 7.4. Carboprost Tromethamine Market - Europe
  • 7.4.1. Europe: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.4.2. Europe: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.4.3. Carboprost Tromethamine Market - UK
    • 7.4.3.1. UK: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.4.3.2. UK: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.4.4. Carboprost Tromethamine Market - France
    • 7.4.4.1. France: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.4.4.2. France: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.4.5. Carboprost Tromethamine Market - Germany
    • 7.4.5.1. Germany: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.4.5.2. Germany: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.4.6. Carboprost Tromethamine Market - Italy
    • 7.4.6.1. Italy: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.4.6.2. Italy: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.4.7. Carboprost Tromethamine Market - Spain
    • 7.4.7.1. Spain: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.4.7.2. Spain: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.4.8. Carboprost Tromethamine Market - Netherlands
    • 7.4.8.1. Netherlands: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.4.8.2. Netherlands: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.4.9. Carboprost Tromethamine Market - Russia
    • 7.4.9.1. Russia: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.4.9.2. Russia: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
• 7.5. Carboprost Tromethamine Market - Asia Pacific
  • 7.5.1. Asia Pacific: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.5.2. Asia Pacific: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.5.3. Carboprost Tromethamine Market - China
    • 7.5.3.1. China: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.5.3.2. China: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.5.4. Carboprost Tromethamine Market - India
    • 7.5.4.1. India: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.5.4.2. India: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.5.5. Carboprost Tromethamine Market - Malaysia
    • 7.5.5.1. Malaysia: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.5.5.2. Malaysia: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.5.6. Carboprost Tromethamine Market - Japan
    • 7.5.6.1. Japan: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.5.6.2. Japan: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.5.7. Carboprost Tromethamine Market - Indonesia
    • 7.5.7.1. Indonesia: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.5.7.2. Indonesia: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.5.8. Carboprost Tromethamine Market - South Korea
    • 7.5.8.1. South Korea: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.5.8.2. South Korea: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
• 7.6. Carboprost Tromethamine Market - Middle East & Africa
  • 7.6.1. Middle East & Africa: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.6.2. Middle East & Africa: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.6.3. Carboprost Tromethamine Market - Saudi Arabia
    • 7.6.3.1. Saudi Arabia: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.6.3.2. Saudi Arabia: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.6.4. Carboprost Tromethamine Market - UAE
    • 7.6.4.1. UAE: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.6.4.2. UAE: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.6.5. Carboprost Tromethamine Market - Israel
    • 7.6.5.1. Israel: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.6.5.2. Israel: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.6.6. Carboprost Tromethamine Market - South Africa
    • 7.6.6.1. South Africa: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.6.6.2. South Africa: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
• 7.7. Carboprost Tromethamine Market - Latin America
  • 7.7.1. Latin America: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.7.2. Latin America: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.7.3. Carboprost Tromethamine Market - Mexico
    • 7.7.3.1. Mexico: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.7.3.2. Mexico: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.7.4. Carboprost Tromethamine Market - Brazil
    • 7.7.4.1. Brazil: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.7.4.2. Brazil: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)
  • 7.7.5. Carboprost Tromethamine Market - Argentina
    • 7.7.5.1. Argentina: Carboprost Tromethamine Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.7.5.2. Argentina: Carboprost Tromethamine Market, by Application, 2019-2032 (USD Million)

8. Competitive Landscape

• 8.1. Expansion and Acquisition Analysis
  • 8.1.1. Expansion
  • 8.1.2. Acquisitions
• 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

• 9.1. Baxter International Inc.
  • 9.1.1. Company Overview
  • 9.1.2. Financial Performance
  • 9.1.3. Product Benchmarking
  • 9.1.4. Recent Development
• 9.2. Bristol Myers Squibb Company
  • 9.2.1. Company Overview
  • 9.2.2. Financial Performance
  • 9.2.3. Product Benchmarking
  • 9.2.4. Recent Development
• 9.3. Ferring Pharmaceuticals Inc.
  • 9.3.1. Company Overview
  • 9.3.2. Financial Performance
  • 9.3.3. Product Benchmarking
  • 9.3.4. Recent Development
• 9.4. Fresenius Kabi USA
  • 9.4.1. Company Overview
  • 9.4.2. Financial Performance
  • 9.4.3. Product Benchmarking
  • 9.4.4. Recent Development
• 9.5. Hikma Pharmaceuticals PLC
  • 9.5.1. Company Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Benchmarking
  • 9.5.4. Recent Development
• 9.6. JHP Pharmaceuticals, LLC
  • 9.6.1. Company Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Benchmarking
  • 9.6.4. Recent Development
• 9.7. LGM Pharma
  • 9.7.1. Company Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Benchmarking
  • 9.7.4. Recent Development
• 9.8. Pfizer Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Benchmarking
  • 9.8.4. Recent Development
• 9.9. Pharmacia and Upjohn Company LLC (a division of Pfizer Inc.)
  • 9.9.1. Company Overview
  • 9.9.2. Financial Performance
  • 9.9.3. Product Benchmarking
  • 9.9.4. Recent Development
• 9.10. Sandoz Inc. (a Novartis Division)
  • 9.10.1. Company Overview
  • 9.10.2. Financial Performance
  • 9.10.3. Product Benchmarking
  • 9.10.4. Recent Development
• 9.11. Sun Pharmaceutical Industries Ltd.
  • 9.11.1. Company Overview
  • 9.11.2. Financial Performance
  • 9.11.3. Product Benchmarking
  • 9.11.4. Recent Development
• 9.12. Teva Pharmaceutical Industries Ltd.
  • 9.12.1. Company Overview
  • 9.12.2. Financial Performance
  • 9.12.3. Product Benchmarking
  • 9.12.4. Recent Development
• 9.13. Upsher-Smith Laboratories, LLC
  • 9.13.1. Company Overview
  • 9.13.2. Financial Performance
  • 9.13.3. Product Benchmarking
  • 9.13.4. Recent Development
• 9.14. West-Ward Pharmaceuticals Corp. (a subsidiary of Hikma Pharmaceuticals PLC)
  • 9.14.1. Company Overview
  • 9.14.2. Financial Performance
  • 9.14.3. Product Benchmarking
  • 9.14.4. Recent Development
• 9.15. Zoetis Inc.
  • 9.15.1. Company Overview
  • 9.15.2. Financial Performance
  • 9.15.3. Product Benchmarking
  • 9.15.4. Recent Development